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The DNA damage response comprises DNA repair, cell-cycle check-
point control, and DNA damage-induced apoptosis that collectively
promote genomic integrity and suppress tumorigenesis. Previ-
ously, we have shown that the Chk2 kinase functions indepen-
dently of the Mre11 complex (Mre11, Rad50, and Nbs1) and ATM
in apoptosis and suppresses tumorigenesis resulting from hypo-
morphic alleles of Mre11 or Nbs1. Based on this work, we have
proposed that Chk2 limits the oncogenic potential of replication-
associated DNA damage. Here we further address the role of Chk2
and damage-induced apoptosis in suppressing the oncogenic po-
tential of chromosome breaks. We show that loss of Chk2 or a
mutation in p53 (R172P), which selectively impairs its function in
apoptosis, rescued the lethality of mice lacking Lig4, a ligase re-
quired for nonhomologous end-joining (NHEJ) repair of DNA dou-
ble-strand breaks in G0/G1. In contrast to Lig4−/−p53−/−mice, Lig4−/−
Chk2−/− and Lig4−/−p53R172P/R172P mice were not prone to organ-
speciﬁc, rapid tumorigenesis. Although the severe NHEJ deﬁciency
of Lig4−/− was a less potent initiator of tumorigenesis in the
p53R172P/R172P and Chk2−/− backgrounds, where p53 cell-cycle func-
tions are largely intact, even mild defects in the intra-S and G2/M
checkpoints caused bymutations inNbs1 are sufﬁcient to inﬂuence
malignancy in p53R172P/R172P mice. We conclude that the oncogenic
potential of double-strand breaks resulting from NHEJ deﬁciency is
highly restricted by nonapoptotic functions of p53, such as the G1/S
checkpoint or senescence, suggesting that the particular facets of
the DNA damage response required for tumor suppression are dic-
tated by the proliferative status of the tumor-initiating cell.
chromosome instability | kinase signaling | tumor suppressor
Following the detection of DNA lesions, the DNA damage re-sponse (DDR) coordinates DNA repair, cell-cycle checkpoints,
and specialized programs, such as apoptosis and senescence, to
prevent genomic instability (1).DDRgenes frequently aremutated
in chromosome instability and cancer predisposition syndromes,
highlighting the role of the DDR in suppressing malignancy (2).
Markers of DDR activation are observed readily in premalignant
lesions, leading to the hypothesis that the DDR is an inducible
barrier to tumorigenesis (3). Indices of DDR activation are re-
duced as tumors evolve, suggesting that selection against aspects of
DNA damage signaling accompany tumor progression (1).
DNA double-strand breaks (DSBs) are physiologically im-
portant lesions, because they can be cytotoxic or cytostatic and
generate oncogenic translocations (2, 4). Two major pathways of
DSB repair are used in the cell: nonhomologous end-joining
(NHEJ) and homology-directed repair (HDR). The use of HDR
is cell cycle dependent, regulated by the activity of cyclin-de-
pendent kinases and, in some cases, by the cell cycle-dependent
expression or stability of required factors (5). HDR preferen-
tially uses the sister chromatid as a template and thus is sub-
stantially less error-prone than NHEJ, which typically results in
the deletion or addition of DNA sequences at the junction of
repair. Deﬁciencies in both pathways have been linked to chro-
mosomal instability, DNA damage sensitivity, and cancer pre-
disposition, reﬂecting the hazards posed by DSBs (1).
The DDR is initiated by the recognition of DSBs that is me-
diated primarily by the Mre11 complex, consisting of Mre11,
Rad50, and Nbs1. DSB engagement by the Mre11 complex is
required for subsequent activation of ATM, an apical kinase in
the DDR (2). ATM and related kinases are estimated to modify
more than 700 substrates in response to DNA damage on con-
sensus SQ/TQ sites (6, 7). Among these substrates are key regu-
lators of cell-cycle checkpoints, DNA repair factors, and proteins
that regulate apoptosis and senescence, accounting for the broad
physiological impact of DDR functions (8).
Arguably one of the most important ATM substrates is the
tumor suppressor p53. p53 controls the G1/S cell-cycle check-
point and is required for both apoptosis and senescence in various
cellular contexts (9). Deﬁciency of p53 results in severe predis-
position to lymphoma in the mouse (10, 11). Mice harboring a
separation-of-function mutation in p53, p53R172P, in which its
apoptotic function is abolished but its inﬂuence on the G1/S
checkpoint and the induction of senescence remain intact, have
been established. The spectrum and kinetics of tumor de-
velopment in p53R172P/R172P mice are markedly distinct from
those of p53−/− mice (12). p53R172P/R172P mice have a late-onset
tumor phenotype, exhibiting lymphomas and a variety of solid
tumors, suggesting that senescence and G1/S checkpoint func-
tions delay tumorigenesis in the context of apoptotic deﬁciency.
Consistent with this view, the p53R172P allele retards the de-
velopment of lymphomas resulting from Myc overexpression
compared with p53 heterozygosity (13). Together, these data in-
dicate that the apoptotic functions of p53 are not sufﬁcient for its
role as a tumor suppressor.
p53 functions are activated by DSBs induced in G1 cells,
leading to the activation of apoptotic as well as nonapoptotic
responses. Lig4−/− and Xrcc4−/− mice, which lack key compo-
nents of the NHEJ machinery, exhibit perinatal lethality and are
associated with high levels of DSBs in areas of the brain con-
taining differentiated and largely nondividing cell populations
(14, 15). p53 deﬁciency rescues the lethality of Lig4−/− and
Xrcc4−/− mice, but Lig4−/− p53−/− and Xrcc4−/− p53−/− mice have
rapid onset of pro– and pre–B-cell lymphomas as well as me-
dulloblastomas with complete penetrance (16, 17). These data
indicate that defective NHEJ-mediated repair of DSBs arising in
G1 cells, such as those induced during antigen-receptor gene
assembly and in differentiated CNS components, are highly on-
cogenic when p53 functions are lost (4).
Previously, we provided evidence that the Chk2 kinase sup-
pressed the oncogenic potential of DNA replication-associated
DNA damage through crosses with mice harboring mutations in
Mre11 (Mre11ATLD1/ATLD1) and Nbs1 (Nbs1ΔB/ΔB) (18). This in-
terpretation was based on the fact that those Mre11 complex
alleles primarily affect the DDR in the S and G2 phases of the
cell cycle and exhibit marked tumor predisposition in the context
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of Chk2 deﬁciency (19, 20). In contrast, Chk2 deﬁciency did not
enhance tumorigenesis in PrkdcScid mice, in which DSBs induced
in G1 cells during antigen-receptor gene assembly are not re-
paired (18). These data support the view that Chk2 tumor-sup-
pressive activity may be relevant primarily for DNA damage that
arises during S or G2 phase (18).
In this study, we examine genetic contexts in which defective
apoptotic responses resulting from either p53 or Chk2 mutation
are juxtaposed with DDR mutations that increase DNA damage
in G1, S, or G2/M phases of the cell cycle. G1 DNA damage is
enhanced in Lig4−/− mice. Unlike Lig4−/− p53−/− mice, Lig4−/−
Chk2−/− and Lig4−/− p53R172P/R172P mice were not highly prone
to the rapid development of lymphoma and medulloblastoma.
Together, these outcomes suggest that the oncogenic potential of
breaks generated by NHEJ deﬁciency is restricted by non-
apoptotic p53 functions such as senescence or the imposition of
the G1/S checkpoint. In contrast, Nbs1ΔC and Nbs1ΔB mutations,
which impair the intra–S-phase and G2/M checkpoints, en-
hanced tumorigenesis in p53R172P/R172P mice. Combined with
previous data regarding tumor predisposition in Nbs1ΔB/ΔB
Chk2−/− mice, these results provide evidence for the tumor-
suppressive inﬂuence of the intra-S and G2/M checkpoints.
Collectively, the data presented indicate that the relative potency
of apoptosis or senescence for tumor suppression is dependent
on the DNA repair or cell-cycle checkpoint status of cancer-
initiating cells.
Results
Nbs1 Mutations Inﬂuence Tumorigenesis in p53R172P/R172P Mice. In
p53-deﬁcient mice, the DNA damage-dependent induction of
apoptosis, senescence, and the G1/S checkpoint are lost. Because
senescence and the G1/S checkpoint are intact in p53R172P/R172P
mice, these animals provide a means to assess the importance of
p53-dependent apoptosis for suppressing the oncogenic potential
of DNA damage associated with DNA replication (12). We
combined p53R172P/R172P with two Nbs1 mutants, Nbs1ΔB and
Nbs1ΔC, which impair the response to DNA damage in S phase.
The N terminus of Nbs1 contains a Forkhead-associated (FHA)
and tandem Brca1 C-terminal (BRCT) phosphopeptide binding
motifs, and the C terminus of Nbs1 contains a conserved domain
that contributes to the physical interaction between the Mre11
complex and ATM (2, 21, 22). The Nbs1ΔC mutant lacks the C-
terminal domain and exhibits an intra–S-phase checkpoint de-
fect, as well as a defect in apoptosis, whereas the Nbs1ΔB mutant,
lacking the FHA and ﬁrst BRCT domain, is defective in both the
intra-S and G2/M checkpoints but is competent for apoptosis
(19, 23).
Relative to p53R172P/R172P alone, both p53R172P/R172P Nbs1ΔC/ΔC
and p53R172P/R172P Nbs1ΔB/ΔB double mutants exhibited reduced
survival, a more rapid onset of tumorigenesis, and alterations in
tumor spectrum (Fig. 1 A–D and Tables S1–S7). These results
reveal that the intra–S-phase checkpoint defects associated with
Nbs1ΔC/ΔC decrease the latency of tumorigenesis. The reduction
in latency was even more pronounced in Nbs1ΔB/ΔB p53R172P/R172P
mutants than in Nbs1ΔC/ΔC p53R172P/R172P mutants, indicating
that tumor suppression was impaired to a greater extent by
defects in both the intra-S and G2/M checkpoints, present in
cells from Nbs1ΔB/ΔB, than by defects in the intra-S checkpoint
alone. We observed a marked increase in chromosome instability
in cell cultures (Fig. 1E and Fig. S1) from both Nbs1ΔC/ΔC
p53R172P/R172P and Nbs1ΔB/ΔB p53R172P/R172P animals as compared
with single mutants, supporting the interpretation that the intra-S
and G2/M checkpoints contribute to tumor suppression by pro-
moting genomic integrity. This outcome is in contrast to the ob-
servation that tumors from p53R172P/R172P animals exhibited normal
ploidy and few chromosomal aberrations, further underscoring the
contributions of the intra-S and G2/M checkpoints to chromo-
some stability (12).
C
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Fig. 1. Mutations in Nbs1 inﬂuence tumor predisposition in p53R172P/R172P mice. (A) Overall and tumor-free survival in cohorts of p53R172P/R172P (n = 32/18),
Nbs1ΔC/ΔC p53R172P/R172P (n = 26/21), and p53R172P/R172P Nbs1ΔB/ΔB (n = 26/17) double mutants. Mutations inNbs1 lead to a reduction in the survival of p53R172P/R172P
animals (P < 0.0001, p53R172P/R172P vs. p53R172P/R172P Nbs1ΔB/ΔB; P = 0.0002, p53R172P/R172P vs. p53R172P/R172P Nbs1ΔC/ΔC using the Mantel–Cox log rank test). (B) The
percentage of mice in the cohort that were tumor free or that had one or more than one tumor. (C) The tumor spectrum and percentage of mice developing
tumors in each genotype are graphed with uncharacterized tumors shown in yellow. More detailed information is provided in Tables S1–S7. (D) Histological
examples of H&E-stained tumors in p53R172P/R172P Nbs1ΔB/ΔB or p53R172P/R172P Nbs1ΔC/ΔC mice. Shown from left to right are (1) a multicentric lymphoma (magni-
ﬁcation: 40×); (2) hemangiosarcoma (magniﬁcation: 25×); (3) primitive neuroectodermal tumor in the cerebellum; and (4) vulva with squamous cell carcinoma
(magniﬁcation: 100×) with arrows indicating inﬁltrative squamous cells. (E) Metaphase chromosome analysis of primary earﬁbroblasts of the indicated genotype
with percentages of chromatid (cd) and chromosome (ch) breaks, fusions, fragments, and total aberrations per chromosome. Examples are shown in Fig. S1.
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Defective p53-Dependent Apoptosis Rescues the Viability of Lig4−/−.
The combination of p53 R172P/R172P mice with mutations af-
fecting the Mre11 complex indicated that chromosomal in-
stability associated with intra-S and G2/M checkpoint defects
enhances tumorigenesis when apoptosis is impaired. The in-
stability in those mutants is attributable primarily to impaired
responses to DNA damage that arises during S phase as a result
of DNA replication (24). Deﬁciency of DNA ligase 4 (Lig4−/−)
severely impairs NHEJ, and Lig4−/− mice die in late embryo-
genesis. These mice exhibit extensive apoptosis in regions of the
developing brain that contain ultimately postmitotic cells, in-
cluding differentiated neurons (15). The lethality of Lig4−/− is
rescued by the deletion of p53, and the rescued mice exhibit
high-penetrance, early-onset medulloblastomas and B-cell lym-
phomas that exhibit gene duplications and recurrent trans-
locations (17, 25, 26). To delineate the tumor-suppressive
functions of apoptosis in response to DSBs in G1 cells, we
crossed Lig4−/− mice with Nbs1ΔC/ΔC, Chk2−/−, and p53R172P/R172P
mice and assessed the viability and development of the embryonic
brain. The viability of Lig4−/− mice was rescued by Chk2 deﬁ-
ciency and the p53R172P allele, but Lig4−/− Nbs1ΔC/ΔC mice were
inviable (Fig. 2 A and B and Table S8).
The degree of rescue in these settings, as inferred from size of the
animals and level of CNS apoptosis, was correlated with the relative
severity of the apoptotic defects in p53R172P/R172P andChk2−/−mice.
Lig4−/− p53R172P/R172P pups were less severely runted than Lig4−/−
Chk2−/− and showed normal brain development and low levels of
cleaved caspase-3 staining (Fig. 2 B–D; in D, subpanels 2 and 8
compared with subpanels 1 and 7). In contrast, gross morphological
defects were evident in the brains of Lig4−/−Chk2−/−mice (Fig. 2D,
subpanels 3 and 4 compared with subpanels 5 and 6). These brains
contained limited areas of apoptotic cells, but, overall, Lig4−/−
Chk2−/− doublemutants weremuch less affected thanLig4−/− single
mutants (Fig. 2D, subpanels 9 and 10 compared with subpanel 7).
These results are consistent with data suggesting a role for Chk2 in
genotoxic stress-induced checkpoint activation in the brain (27).
The phenotypic rescue observed in Lig4−/− p53R172P/R172P and
Lig4−/− Chk2−/− double mutants was incomplete: Immune sys-
tem development was not rescued (Fig. 2E), and both Lig4−/−
Chk2−/− and, to a lesser extent, Lig4−/− p53R172P/R172P mice
exhibited precocious degeneration of the seminiferous tubules
(Fig. 2F). Cumulatively, these data indicate that the embryonic
lethality of Lig4 deletion is dependent on apoptosis mediated by
Chk2 and p53 and that the myriad pathologies evident are the
consequences of impaired NHEJ-mediated DSB repair and the
induction of p53-dependent cell-cycle regulatory programs.
Cell-Cycle Regulatory Functions of p53 Inﬂuence Tumorigenesis in
Lig4−/− Animals. As noted previously, rescue of Lig4−/− viability by
p53 deﬁciency results in rapid-onset pro–B-cell lymphoma and
A B C
D
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Fig. 2. Apoptotic defects are sufﬁcient to rescue the viability of Lig4-deﬁcient animals. (A) Graphical representationof expectedvs. observednumber of pups based
onMendelian inheritance of alleles. Details of breeding schemes and numbers are provided in Table S8. (B) Representative images of 2-mo-oldmice of the indicated
genotypes. (C) Analysis of changes in pupweight of the indicated genotypes over 3mo. (D) Immunohistochemical analysis of brainmorphology in E13.5 embryos of
the indicatedgenotypes. (Upper) H&E staining. (Lower) Cleaved caspase-3 staining.Arrows in panels 9 and10 indicate rare clusters of caspase 3 positive cells. (E) B220
staining of mesenteric lymph nodes. (Left) Normal mesenteric lymph node of a p53R172P/R172P mouse. (Center and Right) Marked lymphoid atrophy/hypoplasia
observed in all Lig4-nullmice; genotypes are indicated. (F) Testicular pathology observed in 4/4 Lig4−/−Chk2−/− and 9/15 Lig4−/−p53R172P/R172Pmice. (1) Degeneration
of seminiferous tubules observed in Lig4−/− Chk2−/−mice between 3.2 and 7.1 (shown)mo. (2) Cross-section of 2.2-mo-old Lig4−/− p53R172P/R172P epididymis showing
pleomorphic epithelial cells with karyomegaly (blue arrows) and vacuoles. (3) Variable loss of spermatogonia and primary and secondary spermatocytes observed in
seminiferous tubules of the testes in a p53R172P/R172P mouse (age 14.8 mo). (4) Normal testes pathology in a p53R172P/R172P mouse (age 11.3 mo).
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medulloblastoma with complete penetrance (16, 17). Viability of
Lig4−/− mutants was rescued by p53R172P/R172P and Chk2−/−,
but lifespan was reduced in both double mutants. Nevertheless,
Lig4−/− Chk2−/− mice were not tumor prone, and Lig4−/−
p53R172P/R172P mice died less often from tumors than did Lig4−/−
p53−/− or p53R172P/R172P mice (Fig. 3 A–C) (12, 16). Microscopic
analysis identiﬁed few lesions in a Lig4−/− Chk2−/− cohort, with
only 1 of 15 mice exhibiting a granulosa cell tumor (Fig. 3C). In
contrast to a previous report (28), the tumor spectrum of Lig4−/−
p53R172P/R172P mice was similar to that of p53R172P/R172P mice,
although the percentage of mice developing tumors was reduced
relative to mice with the p53R172P/R172P mutation alone (Fig. 3 A–
C and Table S4). TheLig4−/− p53R172P/R172Pmice that did develop
tumors did so more rapidly than did p53R172P/R172P mice, in-
dicating that defective NHEJ may accelerate tumorigenesis
through breakage-induced chromosomal rearrangements. Unlike
Lig4−/− p53−/−mice, which succumb to tumors before 3 mo of age,
Lig4−/− p53R172P/R172P mice had a longer median survival of 6.6
mo and developed few lymphomas and no medulloblastomas
(Fig. 3C) (16, 17). Heterozygosity of Lig4, which has been shown
to accelerate tumorigenesis in Ink4a/arf−/−mice, did not alter the
kinetics of tumor development but altered the tumor spectrum
compared with that of p53R172P/R172P mice (Fig. 3 A–D) (29).
In p53-null backgrounds, it has been reported that loss of
NHEJ leads to an increase in chromosomal translocations in
both lymphomas and medulloblastomas (25, 26). We examined
chromosomal spreads from primary ﬁbroblasts derived from
Lig4−/− p53R172P/R172P embryos to determine if increased geno-
mic instability was evident. We found a marked increase in the
number of chromosomal aberrations, particularly fusions and
rearrangements, suggesting that a propensity for chromosomal
translocations caused by canonical NHEJ deﬁciency may con-
tribute to tumorigenesis in Lig4−/− p53R172P/R172P animals (Fig.
3E). Together these data indicate that a partial (Chk2−/−) or
complete (p53R172P/R172P) apoptotic defect is sufﬁcient to rescue
the lethality of Lig4 deﬁciency but not to predispose the bearers
to early-onset tumors of the CNS or immune system that are
observed in the complete absence p53 function. Further, these
results demonstrate that the DNA damage-induced activation of
nonapoptotic p53-dependent signaling pathways can provoke
substantial premature mortality in the absence of tumorigenesis.
Nbs1 and Chk2 Promote Apoptosis in Parallel Pathways. In previous
work, we found that ATM and Chk2 independently inﬂuence p53-
dependent apoptosis, indicated by the observation that the apo-
ptotic defects in Atm−/− and Chk2−/− mutants were additive. In
contrast, Nbs1ΔC/ΔC was largely epistatic with Atm−/−, consistent
with their functioning in the same pathway (23). Because loss of
Chk2 but not deletion of the C terminus of Nbs1 was sufﬁcient to
rescue Lig4 deﬁciency (Fig. 2A), we hypothesized that the Nbs1ΔC
allele would inﬂuence apoptosis independently of Chk2. To ad-
dress this possibility, we generated Nbs1ΔC/ΔC Chk2−/− double-
mutant mice and cell cultures. The apoptotic defect of Nbs1ΔC/ΔC
Chk2−/−wasmore severe than either singlemutant and was similar
A
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Fig. 3. The cell-cycle functions of p53 restrict Lig4-mediated tumorigenesis. (A) Overall and tumor-free survival of Lig4-deﬁcient p53R172P/R172P (reproduced
from Fig. 1A for a point of comparison; statistical analysis is presented in Tables S1–S7), p53R172P/R172P (n = 32/18), Lig4+/− p53R172P/R172P (n = 39/21), Lig4−/−
p53R172P/R172P (n = 40/28), and Lig4−/− Chk2−/− (n = 21/15) mice. (B) The percentage of mice in the cohort that were tumor free or had one or more than one
tumor. (C) Tumor spectrum and percentage of tumors observed in cohorts of the indicated genotypes. (D) Representative images of tumors from the in-
dicated genotypes. (1) Osteosarcoma of the oral–nasal cavity with inﬁltration around the tooth (*) with erosion of the maxilla and osteoid formation (arrow)
displacing the overlying soft tissue. (2) Cholangiosarcoma impinging upon the liver (right side). (3) Adenocarcinoma of the small intestine, Brunner’s glands.
(4) Early-onset (6.6 mo) granulosa cell tumor of the ovary. (E) Metaphase chromosome analysis of primary embryo ﬁbroblasts of the indicated genotype.
Examples are shown in Fig. S1.
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in magnitude to that of p53−/− or p53R172P/R172P (Fig. 4A). Corre-
lating with this defect, we observed reduced p53 phosphorylation
and stabilization in Nbs1ΔC/ΔC Chk2−/− cells compared with either
single mutant or wild-type controls (Fig. 4B). The strong additive
phenotype of the Nbs1ΔC/ΔC Chk2−/− thymocytes indicated that
Nbs1 and Chk2 functioned in parallel pathways and that p53-
dependent apoptosis was severely impaired in response to ioniz-
ing radiation in these animals.
We compared the apoptotic and cell-cycle checkpoint responses
of Nbs1ΔC/ΔC Chk2−/− double mutants with those seen with the
p53R172P/R172P mutation, which impairs apoptosis but retains the
cell-cycle functions (12). We found that, like p53R172P/R172P, cul-
tures of Nbs1ΔC/ΔC Chk2−/− cells had only a minor G1/S defect
compared with wild type and a strong defect in ionizing radiation-
induced apoptosis in thymocytes (Fig. 4 A and C and Fig. S2). As
we have reported previously, a normal G1/S response was ob-
served in mouse embryo ﬁbroblasts (MEFs) from Nbs1ΔC/ΔC (Fig.
4C and Fig. S2) (23). Thus, Nbs1ΔC/ΔC Chk2−/− mice phenocopy
p53R172P/R172P mice, exhibiting pronounced apoptotic defects but
leaving ionizing radiation-dependent induction of the G1/S cell-
cycle checkpoint intact.
Nbs1ΔC/ΔC Chk2−/− mice did not phenocopy the cancer suscepti-
bility of p53R172P/R172P animals. p53R172P/R172P andNbs1ΔC/ΔCChk2−/−
mice were followed over the course of 20 mo (Fig. 4D). Although
tumors arose with a mean latency of ∼11 mo in p53R172P/R172P
mice, as previously reported (12), tumorigenesis was not observed
in the Nbs1ΔC/ΔC Chk2−/− cohort (Fig. 4D). These data likely in-
dicate that p53 regulation induced by DNA damage is partially
intact inNbs1ΔC/ΔC Chk2−/−mice or that the p53R172P allele blunts
the apoptotic response to a broader spectrum of lesions that
promote tumorigenesis than the mutations in Nbs1 and Chk2,
which are defective primarily in the response to DNA DSBs.
Discussion
With respect to the role of the DDR in tumor suppression, these
data shed light on the relationship of apoptosis to cell-cycle
regulation, on one hand, and to DSB repair, on the other. In
either case, defects in the DNA damage-dependent induction of
apoptosis, such as those evident in p53R172P/R172P and Chk2−/−
mutations, are correlated with increased oncogenic potential.
Nonapoptotic DDR signaling outcomes such as activation of the
cell-cycle checkpoint mediated by the Mre11 complex and in-
duction of senescence by p53 suppress that potential, as indicated
by the fact that individual or combined loss of G1/S, intra-S, and
G2/M checkpoint control enhance tumorigenesis in p53R172P/R172P
mice (18, 30). This ﬁnding is particularly notable, because tu-
morigenesis in p53R172P/R172P mice is enhanced by the loss of p21
and the G1/S checkpoint or by the loss of Nbs1ΔC/ΔC and the intra-
S checkpoint in the absence of major DNA repair defects per se.
DSB repair deﬁciency also enhances the oncogenic potential
of apoptotic defects and appears to do so in a cell cycle-speciﬁc
manner. This point is starkly illustrated by the observation that
NHEJ defects, which are primarily relevant in G0/G1 cells, en-
hance tumorigenesis most efﬁciently when the G1/S checkpoint
is impaired (e.g., in Lig4−/− p53−/− as compared with Lig4−/−
p53R172P/R172P or Lig4−/− Chk2−/− mutants) (16). On the other
hand, genetic analysis revealed that Chk2 suppresses tumori-
genesis when G2/M checkpoint signaling and repair are defective
but not in response to the absence of NHEJ (Fig. 3 and refs. 18,
31, and 32). The latter result is particularly striking, because it
demonstrates that both the severity of the defect in apoptosis
and the status of p53-dependent cell-cycle regulation moderate
the inﬂuence of NHEJ deﬁciency on tumorigenesis. Hence,
depending on the status of p53 signaling, chromosomal breakage
arising from defective NHEJ can provoke tumorigenesis, tumor-
free premature mortality, or a combination of both outcomes.
Both Nbs1ΔB and Nbs1ΔC alleles inﬂuence the tumor spectrum
of p53R172P/R172P mutants, but only Nbs1ΔB promotes tumori-
genesis in Chk2−/− mice, suggesting that particular functions of
the Mre11 complex are important when apoptotic defects are
less severe. A potential candidate for this activity is DSB re-
section, the conversion of dsDNA to ssDNA via nuclease activity
(33). In yeast, DSB resection is required for both efﬁcient G2/M
checkpoint arrest and HDR, and this process has been proposed
to underlie the DSB-induced activation of ATR and Chk1 in
mammalian cells (34–36). Because the G2/M checkpoint and
HDR are defective in Nbs1ΔB and other alleles that lead to tu-
morigenesis in mice lacking Chk2 but are intact in Nbs1ΔC mice,
we hypothesize that defects in resection may promote the gen-
eration of oncogenic lesions that normally are eliminated by Chk2
activity through apoptosis or additional regulatory functions (18,
31, 37). Because the cell-cycle checkpoint defects of the Nbs1ΔC
allele are restricted to S phase, these defects inﬂuence tumori-
genesis only in the context of the more severe apoptotic defects of
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Fig. 4. Defects in ionizing radiation-induced apoptosis are genetically sepa-
rable from cell-cycle regulation. (A) Apoptosis assessed by ﬂow cytometry of
thymocytes of the indicated genotype 20 h after ionizing radiation treatment
with a range of doses. Results are compiled from triplicate samples fromat least
two different animals of each genotype. (B) Western blotting of p53 serine 18
phosphorylation and total p53 levels following treatment with 0-, 0.5-, or 5-Gy
ionizing radiation in primary cell cultures from the indicated genotypes. (C)
G1/S checkpoint in early-passage MEF cultures. S-phase ratios (%BrdU+ cells in
ionizing radiation or mock treated samples/average %BrdU+ in mock treated
samples) are plotted. Results are the average of two to four experiments per-
formed in triplicate for each genotype. Error bars denote SD. Results for in-
dividual cultures are shown in Fig. S2. (D) Cohort survival of Nbs1ΔC/ΔC (n = 45),
Chk2−/− (n = 42),Nbs1ΔC/ΔC Chk2−/− (n = 40), and p53R172P/R172P (n = 32) mice over
20 mo. (E) Contributions of the DDR to tumor suppression. Mutations in NHEJ,
such as the Prkdcscid or Lig4-null alleles, block DSB repair primarily in G1/G0-
phase cells whereHDR is not operative. The oncogenic potential of the resulting
unrepaired breaks is suppressed by p53, with the cell-cycle functions (indicated
in bold) having a primary inﬂuence. In S/G2-phase cells, the activation of apo-
ptosis (indicated in bold) through p53 and Chk2 appears to be the primary
mode of suppressing the oncogenic potential of DNA replication-associated
DSBs, the levels of which are elevated by mutations in Mre11 or Nbs1 that
impair the intra-S and G2/M checkpoints (green type).
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p53R172P/R172P mutations. We also cannot rule out the possibility
that p53R172P and Nbs1ΔC alleles have additional defects in vivo
that inﬂuence tumor growth. Considering this possibility, and
given the diverse tumor spectrum, we predict that these additional
functions are unlikely to be tissue speciﬁc.
Collectively, these data illustrate the interdependence of DSB
repair, cell-cycle checkpoints, and apoptosis in the suppression of
malignancy. These results are consistent with a model that in
nondividing cells, which are dependent primarily on NHEJ for
DSB repair, survival is dependent on apoptosis, but the sup-
pression of oncogenesis relies heavily upon the imposition of cell-
cycle regulation by p53 (Fig. 4E). On the other hand, dividing
cells experiencing replicative stress and damage at replication
forks primarily are dependent on both resection-based check-
point and repair responses and on apoptosis to suppress the
subsequent development of chromosomal instability and onco-
genic lesions. Thus, we propose that the DDR barriers that cells
must overcome before becoming initiators of tumorigenesis de-
pend on their proliferative status. A more complete mechanistic
understanding of the individual processes within the DDR in-
volved in tumor suppression and of their interrelationships will be
essential to identify functional biomarkers that will have pre-
dictive value in cancer predisposition, progression, and treatment.
Materials and Methods
Flow Cytometry. Thymocytes were isolated from 7- to 9-mo-old animals and
exposed ex vivo to the indicated doses of ionizing radiation. Twenty hours
after ionizing radiation, cells were stained with Annexin-V FITC and propi-
dium iodide (PI) (Becton Dickinson), and the percentage of double-negative
(viable) cells was determined by ﬂow cytometry and normalized to untreated
cells (apoptotic ratio).
Checkpoint Analysis. The G1/S checkpoint was assessed in early-passage (< p4)
MEFs. Cells were exposed to the indicated doses of ionizing radiation using
an X-ray cabinet and 14 h after treatment were pulse labeled with BrdU for
4 h and stained with anti–BrdU-FITC antibodies and PI (Becton Dickinson).
The percentage of S-phase cells was determined by ﬂow cytometry and
normalized to untreated cells (S-phase ratio).
Immunohistochemistry. Embryonic day (E) 13.5 embryos or moribund mice
were euthanized, ﬁxed in 10% (vol/vol) neutral-buffered formalin, parafﬁ-
nized, and sectioned using standard methods. Serial sections were stained
with H&E or antibodies to cleaved caspase-3 (Millipore).
Mice and Assessment of Tumor Predisposition. Lig4−/−, Chk2−/−, p53R172P/R172P,
p53−/−, and Atm−/−mice were obtained from P. McKinnon (St. Jude Childrens
Research Hospital, Memphis, TN), T. Mak (Ontario Cancer Institute, Ontario,
Canada), G. Lozano (The University of Texas MD Anderson Cancer Center,
Houston, TX), T. Jacks (Massachusetts Institute of Technology, Boston, MA),
and T. Wynshaw Boris (University of California, San Francisco, CA), re-
spectively. Nbs1ΔB and Nbs1ΔC mice were described previously (19, 23). Mice
were raised in a pathogen-free facility and genotyped by PCR (details upon
request). Mice were maintained on a mixed 129/B6 background and moni-
tored for signs of malignancy or distress three to ﬁve times per week. Any
animals with palpable tumors or other signs of distress were euthanized and
processed for pathological analysis. Appropriate National Institutes of Health
guidelines for animal husbandry and treatment were followed.
Western Blotting. Samples were lysed in TNG-150 buffer [50 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 1% Tween-20, 10% (vol/vol) NP40], separated by SDS/
PAGE, and transferred to PVDF membrane (Millipore). Membranes were
probed with antibodies for p53 (CM5; Vector), phospho-S15/18 p53 (Cell Sig-
naling), or SMC1 (Abcam). Primary antibodies were detectedwith appropriate
secondary antibodies conjugated to HRP (Jackson) and visualized by ECL (GE).
ACKNOWLEDGMENTS. We thank Suzana Couto for assistance with patholog-
ical analysis and sample preparation, David Rossell and Evarist Planet of the
Institute for Research in Biomedicine Biostatistics Unit for advice on statistical
analysis, andmembers of the J.H.J.P. and T.H.S. laboratories for critical reading
of the manuscript and discussions. S.S.F. is supported by the Memorial Sloan-
Kettering Cancer Center Brain Tumor Center. J.H.J.P is supported by grants
from the National Institutes of Health, the Geoffrey Beene Foundation, and
the Goodwin Foundation. T.H.S. is a Ramon y Cajal investigator, supported by
Grant SAF2009-10023 from the Ministerio de Ciencia e Innovacion, and was
a Special Fellow of the Leukemia and Lymphoma Society.
1. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease.
Nature 461:1071–1078.
2. Stracker TH, Petrini JH (2011) The MRE11 complex: Starting from the ends. Nat Rev
Mol Cell Biol 12:90–103.
3. Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage
model for cancer development. Science 319:1352–1355.
4. Nussenzweig A, Nussenzweig MC (2010) Origin of chromosomal translocations in
lymphoid cancer. Cell 141:27–38.
5. Heyer WD, Ehmsen KT, Liu J (2010) Regulation of homologous recombination in
eukaryotes. Annu Rev Genet 44:113–139.
6. Matsuoka S, et al. (2007) ATM and ATR substrate analysis reveals extensive protein
networks responsive to DNA damage. Science 316:1160–1166.
7. Mu JJ, et al. (2007) A proteomic analysis of ataxia telangiectasia-mutated (ATM)/ATM-
Rad3-related (ATR) substrates identiﬁes the ubiquitin-proteasome system as a regu-
lator for DNA damage checkpoints. J Biol Chem 282:17330–17334.
8. Ciccia A, Elledge SJ (2010) The DNA damage response: Making it safe to play with
knives. Mol Cell 40:179–204.
9. Iwakuma T, Lozano G (2007) Crippling p53 activities via knock-in mutations in mouse
models. Oncogene 26:2177–2184.
10. Donehower LA, et al. (1992) Mice deﬁcient for p53 are developmentally normal but
susceptible to spontaneous tumours. Nature 356:215–221.
11. Jacks T, et al. (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1–7.
12. Liu G, et al. (2004) Chromosome stability, in the absence of apoptosis, is critical for
suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 36:63–68.
13. Post SM, et al. (2010) p53-dependent senescence delays Emu-myc-induced B-cell
lymphomagenesis. Oncogene 29:1260–1269.
14. Gao Y, et al. (1998) A critical role for DNA end-joining proteins in both lymphogenesis
and neurogenesis. Cell 95:891–902.
15. Orii KE, Lee Y, Kondo N, McKinnon PJ (2006) Selective utilization of nonhomologous
end-joining and homologous recombination DNA repair pathways during nervous
system development. Proc Natl Acad Sci USA 103:10017–10022.
16. Frank KM, et al. (2000) DNA ligase IV deﬁciency in mice leads to defective neuro-
genesis and embryonic lethality via the p53 pathway. Mol Cell 5:993–1002.
17. Lee Y, McKinnon PJ (2002) DNA ligase IV suppresses medulloblastoma formation.
Cancer Res 62:6395–6399.
18. Stracker TH, Couto SS, Cordon-Cardo C, Matos T, Petrini JH (2008) Chk2 suppresses the
oncogenic potential of DNA replication-associated DNA damage. Mol Cell 31:21–32.
19. Williams BR, et al. (2002) A murine model of Nijmegen breakage syndrome. Curr Biol
12:648–653.
20. Theunissen JW, et al. (2003) Checkpoint failure and chromosomal instability without
lymphomagenesis in Mre11(ATLD1/ATLD1) mice. Mol Cell 12:1511–1523.
21. Falck J, Coates J, Jackson SP (2005) Conserved modes of recruitment of ATM, ATR and
DNA-PKcs to sites of DNA damage. Nature 434:605–611.
22. You Z, Chahwan C, Bailis J, Hunter T, Russell P (2005) ATMactivation and its recruitment
to damagedDNA require binding to the C terminus of Nbs1.Mol Cell Biol 25:5363–5379.
23. Stracker TH, Morales M, Couto SS, Hussein H, Petrini JH (2007) The carboxy terminus of
NBS1 is required for induction of apoptosis by theMRE11 complex.Nature 447:218–221.
24. Adelman CA, De S, Petrini JH (2009) Rad50 is dispensable for the maintenance and
viability of postmitotic tissues. Mol Cell Biol 29:483–492.
25. Zhu C, et al. (2002) Unrepaired DNA breaks in p53-deﬁcient cells lead to oncogenic
gene ampliﬁcation subsequent to translocations. Cell 109:811–821.
26. Yan CT, et al. (2006) XRCC4 suppresses medulloblastomas with recurrent trans-
locations in p53-deﬁcient mice. Proc Natl Acad Sci USA 103:7378–7383.
27. SquatritoM, et al. (2010) Loss of ATM/Chk2/p53 pathway components accelerates tumor
development and contributes to radiation resistance in gliomas.Cancer Cell 18:619–629.
28. Van Nguyen T, Puebla-Osorio N, Pang H, Dujka ME, Zhu C (2007) DNA damage-in-
duced cellular senescence is sufﬁcient to suppress tumorigenesis: A mouse model. J
Exp Med 204:1453–1461.
29. Sharpless NE, et al. (2001) Impaired nonhomologous end-joining provokes soft tissue
sarcomas harboring chromosomal translocations, ampliﬁcations, and deletions. Mol
Cell 8:1187–1196.
30. Barboza JA, Liu G, Ju Z, El-Naggar AK, Lozano G (2006) p21 delays tumor onset by
preservation of chromosomal stability. Proc Natl Acad Sci USA 103:19842–19847.
31. Cao L, et al. (2006) ATM-Chk2-p53 activation prevents tumorigenesis at an expense of
organ homeostasis upon Brca1 deﬁciency. EMBO J 25:2167–2177.
32. Fishler T, et al. (2010) Genetic instability and mammary tumor formation in mice
carrying mammary-speciﬁc disruption of Chk1 and p53. Oncogene 29:4007–4017.
33. Mimitou EP, Symington LS (2009) DNA end resection: Many nucleases make light
work. DNA Repair (Amst) 8:983–995.
34. Mimitou EP, Symington LS (2008) Sae2, Exo1 and Sgs1 collaborate in DNA double-
strand break processing. Nature 455:770–774.
35. Zhu Z, Chung WH, Shim EY, Lee SE, Ira G (2008) Sgs1 helicase and two nucleases Dna2
and Exo1 resect DNA double-strand break ends. Cell 134:981–994.
36. Cimprich KA, Cortez D (2008) ATR: An essential regulator of genome integrity. Nat
Rev Mol Cell Biol 9:616–627.
37. Niida H, et al. (2010) Cooperative functions of Chk1 and Chk2 reduce tumour sus-
ceptibility in vivo. EMBO J 29:3558–3570.
9958 | www.pnas.org/cgi/doi/10.1073/pnas.1120476109 Foster et al.
